US Pharmaceuticals & Biotechnology "*ASCO INVITE* KOL Events on Renal Cell ..."

Research evidence excerpt

US Pharmaceuticals & Biotechnology "*ASCO INVITE* KOL Events on Renal Cell ..."

Global Research

21 May 2026ab

US Pharmaceuticals & Biotechnology Equities

Americas*ASCO INVITE* KOL Events on Renal Cell

Carcinoma, Prostate Cancer, Lung Cancer, and Pharmaceuticals

Melanoma MichaelAnalystYee

michael.yee@ubs.com

+1-305-536 9101

We are hosting a series of events at ASCO, including two KOL discussions across renal Ashwani Verma

Analystcell carcinoma, prostate cancer, lung cancer, and melanoma. Please contact your UBS

ash.verma@ubs.com

salesperson or reach out to us if you are interested in attending.

+1-212-713 4059

David Dai

Sunday, May 31 Analyst

david.dai@ubs.com

12:00 PM – 1:30 PM CT: KOL Lunch at ASCO w/Dr. Benjamin Gartrell Discussing +1-212-713 6241

Renal Cell Carcinoma and Prostate Cancer | Ash Verma , David Dai

Discussion Topics — Relevant Tickers: EXEL, MRK, RCUS, KURA, JANX, TLX, NVS

Physician’s interpretation of MRK’s LITESPARK-011 and LITESPARK-022 data;

outlook for Welireg adoption in RCC.

Physician preference for Cabometyx in 1L RCC vs 2L RCC; outlook for breakdown

long-term.

Physician’s view of HIF2a inhibitors: Arcus’ casdatifan vs Welireg data.

Physician’s expectations for EXEL’s upcoming STELLAR-304 readout.

Physician's perspectives on KURA's farnesyl transferase inhibitor (FTI) and recent

FIT-001 Phase 1 data in cabo-refractory ccRCC patients

Physician's view on JANX's JANX007 and ongoing Phase 1b study in 2L taxane-

naïve mCRPC.

Physician's perspective on TLX's TLX-591 in mCRPC and TLX-597 in mHSPC

including early safety and dosimetry data.

Dr. Benjamin Gartrell is an Associate Professor of Oncology in Medical Oncology, an

Associate Professor of Medicine in Oncology and Hematology, and an Associate